Bristol-Myers Squibb Company (BMY) stock analysis

In our weekly check, Bristol-Myers Squibb Company is graded B (A to F). Of 25 checks on debt, profit, cash flow and trend: 19 pass, warnings: 4, red flags: 2.

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company is a Healthcare company (Drug Manufacturers - General) based in the United States, listed on NYSE as BMY.

What our checks show for BMY

Red flags

Warning signs

Strengths

Next earnings report: 2027-02-04

Similar companies

SNY · PFE · GSK · NVO · GILD · AMGN

Questions

What grade does Bristol-Myers Squibb Company (BMY) have?

In our weekly check, Bristol-Myers Squibb Company is graded B (A to F). Of 25 checks on debt, profit, cash flow and trend: 19 pass, warnings: 4, red flags: 2. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of BMY stock?

This week's biggest flags for Bristol-Myers Squibb Company: Gross margin falling, Weak revenue forecast, High debt. In total 6 of 25 checks show a warning or a red flag.

What does Bristol-Myers Squibb Company do?

Bristol-Myers Squibb Company is a Healthcare company (Drug Manufacturers - General) based in the United States, listed on NYSE as BMY.

When does Bristol-Myers Squibb Company report earnings next?

The next earnings report is expected on 2027-02-04. We re-run the checks every week, so the grade can change after it.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-11-14

Open the full analysis